Diabetes Breakthroughs: A Year in Review and What’s on the Horizon for 2024
First of all,
According to the Centers for Disease Control and Prevention (CDC), 422 million people worldwide have diabetes, with 38.4 million of those cases occurring in the United States (World Health Organization, WHO). The majority of these cases occur in low- and middle-income nations. In addition, 98 million persons struggle with prediabetes. Despite these figures, significant progress has been made in the treatment of diabetes, which will be highlighted in 2023.
diabetic Medication for Weight Loss: The use of diabetic drugs for weight loss is a noteworthy breakthrough. Semaglutide, a GLP-1 medication that was first developed to treat diabetes, was shown in the SELECT trial to significantly lower the risk of cardiovascular events in overweight people without diabetes. Tirzepatide is another medication that was originally approved to treat diabetes but has now shown promise as a weight-loss aid, with possible average weight losses of up to 20%.
Advanced Insulin Pump for Type 1 Diabetes: The FDA’s approval of the Beta Bionics iLet ACE Pump and iLet Dosing Decision Software was a revolutionary step in the treatment of type 1 diabetes. Manual carb counting is eliminated when this novel insulin administration device is used in conjunction with a suitable continuous glucose monitor. The algorithm-driven iLet Bionic Pancreas provides a more automated and seamless approach to diabetes care by adjusting to each person’s unique insulin requirements.
Impact of Teplizumab: Teplizumab, an immune therapy licensed in late 2022, has demonstrated promise in postponing the onset of type 1 diabetes, particularly in high-risk individuals like first-degree relatives of those who have the disease. This two-week immunological therapy has shown promise in preventing or considerably delaying the onset of the disease, however it is not a cure.
Type 2 Diabetes and Continuous Glucose Monitors (CGMs):
CGMs, which were previously only used for type 1 diabetes, have become more popular in the past year among those with type 2 diabetes. The benefits of CGMs for type 2 diabetes patients on insulin were shown in the MOBILE research from 2021, which encouraged patients and healthcare professionals to use this device more frequently.
Law for Affordability and Access: Developments in policy during 2023 have enhanced the treatment and control of diabetes. Among the noteworthy developments are Medicare’s expansion of continuous glucose monitor coverage in type 2 diabetes and its extension of Diabetes Prevention Program (MDPP) flexibilities. Furthermore, the Biden administration’s initiative to set a monthly maximum on insulin expenses for Medicare beneficiaries at $35 represents a move in the right direction toward resolving affordability concerns.
Potential Innovations in 2024: Newer medication studies for obesity and type 2 diabetes are anticipated in 2024, with an emphasis on oral GLP-1 receptor activators. More knowledge of the mechanisms underlying weight loss, easier access to novel drugs, and increased use of digital health in diabetes care are among the anticipated developments. Moreover, a coordinated national campaign to prevent diabetes is anticipated, especially in areas like the Diabetes Belt, thanks to the American Diabetes Association (ADA) and the CDC.
In conclusion, 2023 saw a great deal of progress in the treatment of diabetes, ranging from novel insulin delivery methods and immunological therapy to the creative repurposing of drugs for weight loss. The diabetes care environment is expected to undergo additional innovations by 2024, with a focus on pharmacological developments, technology, and governmental programs aiming at prevention and better care access.